gp100 peptide-HLA-A*02:01

The gp100 peptide-HLA-A*02:01 refers to a complex formed between specific peptides derived from the gp100 protein (also known as Melanocyte protein PMEL) and the human leukocyte antigen (HLA) class I molecule HLA-A*02:01. This complex is recognized by CD8+ T cells as part of the immune response against melanoma. The complex consists of the HLA-A*02:01 molecule, Beta-2-microglobulin (B2M), and a specific peptide derived from gp100 protein (e.g., KTWGQYWQV, YLEPGPVTA). These peptides can vary in their binding affinities to HLA-A*02:01, with modified versions sometimes demonstrating stronger binding. Functionally, when presented on the cell surface, this complex is recognized by specific CD8+ T cells, which triggers an immune response against melanoma cells expressing the gp100 protein. The stability of the HLA-A*02:01-peptide complex is a critical determinant of the strength of this immune response, and modifications to the peptide sequence can enhance binding and stability, potentially leading to stronger T cell responses. These complexes are extensively used in research for T cell assays and have significant clinical potential in cancer immunotherapy and vaccine development. Modified gp100 peptides (such as g209-2M) have been developed and used in patients to generate stronger cytotoxic T lymphocyte (CTL) responses against melanoma. Furthermore, a secreted form of the gp100 protein may serve as a melanoma-specific serum biomarker. Recombinant forms of these complexes are typically produced with purification tags, have a calculated molecular weight of approximately 50 kDa, and are available as high-purity lyophilized powders.

Other names

gp100 peptide-HLA-A*02:01 complex

The gp100 peptide-HLA-A*02:01 complex, when presented on the cell surface of melanoma cells, is recognized by specific CD8+ T cells. This recognition triggers an immune response against the melanoma cells expressing the gp100 protein. The stability of the HLA-A*02:01-peptide complex is an important factor in determining the strength of the immune response. Studies have shown that modifications to the peptide sequence can enhance binding affinity and stability, potentially leading to stronger T cell responses.